London & Capital Asset Management Ltd Sells 5,472 Shares of Koninklijke Philips (NYSE:PHG)

London & Capital Asset Management Ltd lessened its position in Koninklijke Philips (NYSE:PHG) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 519,337 shares of the technology company’s stock after selling 5,472 shares during the period. London & Capital Asset Management Ltd’s holdings in Koninklijke Philips were worth $12,116,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. lifted its position in Koninklijke Philips by 4.9% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 16,411 shares of the technology company’s stock valued at $501,000 after purchasing an additional 771 shares during the period. Bank of New York Mellon Corp raised its position in Koninklijke Philips by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 62,767 shares of the technology company’s stock worth $1,916,000 after acquiring an additional 1,414 shares during the period. Cetera Advisor Networks LLC bought a new position in Koninklijke Philips in the first quarter worth approximately $311,000. Citigroup Inc. raised its position in Koninklijke Philips by 1.3% in the first quarter. Citigroup Inc. now owns 36,882 shares of the technology company’s stock worth $1,126,000 after acquiring an additional 483 shares during the period. Finally, Bank of Montreal Can raised its position in Koninklijke Philips by 9.9% in the first quarter. Bank of Montreal Can now owns 94,798 shares of the technology company’s stock worth $3,002,000 after acquiring an additional 8,515 shares during the period. Institutional investors own 13.67% of the company’s stock.

Wall Street Analyst Weigh In

PHG has been the topic of several recent research reports. BNP Paribas downgraded shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research report on Wednesday, February 7th. StockNews.com raised shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Koninklijke Philips Trading Up 2.8 %

Shares of NYSE:PHG traded up $0.56 during trading on Monday, reaching $20.62. The company’s stock had a trading volume of 259,496 shares, compared to its average volume of 989,449. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. Koninklijke Philips has a 12 month low of $17.75 and a 12 month high of $24.27. The firm’s 50 day simple moving average is $20.43 and its two-hundred day simple moving average is $20.85. The stock has a market capitalization of $19.15 billion, a PE ratio of -35.19, a price-to-earnings-growth ratio of 1.04 and a beta of 0.88.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings data on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. On average, research analysts predict that Koninklijke Philips will post 1.52 EPS for the current fiscal year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.